UK markets close in 5 hours 32 minutes
  • FTSE 100

    7,128.43
    -40.25 (-0.56%)
     
  • FTSE 250

    22,744.43
    -168.30 (-0.73%)
     
  • AIM

    1,191.57
    -4.48 (-0.37%)
     
  • GBP/EUR

    1.1752
    +0.0027 (+0.23%)
     
  • GBP/USD

    1.3318
    +0.0040 (+0.30%)
     
  • BTC-GBP

    42,479.09
    -569.58 (-1.32%)
     
  • CMC Crypto 200

    1,441.64
    -27.44 (-1.87%)
     
  • S&P 500

    4,513.04
    -53.96 (-1.18%)
     
  • DOW

    34,022.04
    -461.68 (-1.34%)
     
  • CRUDE OIL

    67.11
    +1.54 (+2.35%)
     
  • GOLD FUTURES

    1,775.40
    -8.90 (-0.50%)
     
  • NIKKEI 225

    27,753.37
    -182.25 (-0.65%)
     
  • HANG SENG

    23,788.93
    +130.01 (+0.55%)
     
  • DAX

    15,306.26
    -166.41 (-1.08%)
     
  • CAC 40

    6,833.48
    -48.39 (-0.70%)
     

Hardman & Co Research: Advanced Oncotherapy (AVO): On the home straight

·2-min read

Hardman & Co Research
15-Nov-2021 / 08:30 GMT/BST

Hardman & Co Research: On the home straight

AVO's goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly de-risked the project. Now, AVO is working on the verification and validation phase, prior to LIGHT being used on the first patients to support CE marking. At its recent investor day, the company highlighted how its differentiated business model is attracting commercial partners that should enhance long-term shareholder returns. Additionally, it is reducing the cost of PT so that it becomes accessible to all.

Please click on the link below for the full report:

https://www.hardmanandco.com/research/corporate-research/on-the-home-straight/

If you are interested in meeting the company, you can register your interest by clicking on the above link

To contact us:

Hardman & Co
1 Frederick's Place

London

EC2R 8AE

www.hardmanandco.com

Follow us on Twitter @HardmanandCo

Contact:

Martin Hall



+44(0)20 3693 7075

 

mh@hardmanandco.com
 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

End of Announcement - EQS News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting